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Naringenin Impairs Two-Pore 
Channel 2 Activity And Inhibits 
VEGF-Induced Angiogenesis
Irene Pafumi1, Margherita Festa  2, Francesca Papacci1, Laura Lagostena3, Cristina Giunta3, 
Vijay Gutla3, Laura Cornara4, Annarita Favia1,5, Fioretta Palombi1, Franco Gambale3,  
Antonio Filippini1 & Armando Carpaneto  3
Our research introduces the natural flavonoid naringenin as a novel inhibitor of an emerging class of 
intracellular channels, Two-Pore Channel 2 (TPC2), as shown by electrophysiological evidence in a 
heterologous system, i.e. Arabidopsis vacuoles lacking endogenous TPCs. In view of the control exerted 
by TPC2 on intracellular calcium signaling, we demonstrated that naringenin dampens intracellular 
calcium responses of human endothelial cells stimulated with VEGF, histamine or NAADP-AM, but not 
with ATP or Angiopoietin-1 (negative controls). The ability of naringenin to impair TPC2-dependent 
biological activities was further explored in an established in vivo model, in which VEGF-containing 
matrigel plugs implanted in mice failed to be vascularized in the presence of naringenin. Overall, 
the present data suggest that naringenin inhibition of TPC2 activity and the observed inhibition of 
angiogenic response to VEGF are linked by impaired intracellular calcium signaling. TPC2 inhibition 
is emerging as a key therapeutic step in a range of important pathological conditions including the 
progression and metastatic potential of melanoma, Parkinson’s disease, and Ebola virus infection. The 
identification of naringenin as an inhibitor of TPC2-mediated signaling provides a novel and potentially 
relevant tool for the advancement of this field of research.
Naringenin (Nar) (5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one) is one of the main flavonoids present in 
the human diet. Epidemiological studies have demonstrated that the consumption of vegetables and fruit with 
a high Nar content, such as citruses and tomatoes or their food products, is associated with a reduced incidence 
of metabolic and chronic-degenerative diseases1, 2. Following this kind of evidence, several in vitro studies have 
shown that Nar interacts with various cellular pathways, highlighting its potential as an antioxidant, antinflam-
matory, chemopreventive and antidegenerative agent3; moreover, Nar was shown to exert anti-angiogenic effects 
in the avian chorio-allantoid membrane model4 while this manuscript was being prepared. Naringenin lowers 
the plasma and hepatic cholesterol concentrations by suppressing HMG-CoA reductase and ACAT in rats fed a 
high-cholesterol diet5. Pre-clinical studies have revealed the potential of Nar and of its precursor naringin in the 
treatment of metabolic and cardiovascular disorders, including hyperlipidemia, hypertension, cardiac toxicity, 
hyperglycemia and diabetes, hepatic steatosis and atherosclerosis2; its therapeutic use to combat various kinds of 
cancer has also been envisaged3. Indeed, Nar exerts chemopreventive and anticancer activity by blocking the pro-
gression and the formation of metastasis in various experimental models of oral6, melanoma7, breast8, 9, colon10, 
lung11 and liver12 cancer. It acts by upregulating many different cell survival proteins or arresting the cell cycle, by 
inducing p53-dependent apoptosis or inhibiting inflammatory processes and, in some cases, by exploiting all of 
these mechanisms13–15. Despite the wealth of evidence on Nar efficacy, a comprehensive view of its mechanism of 
action is still lacking, as is the experimental evidence needed to bridge the gap between multiple cellular targets 
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and biological response. It is worth noting that Nar is known to affect the activity of different calcium-activated or 
calcium-permeable ion channels. At a concentration of 100 μM, Nar induces a threefold increase in the currents 
mediated by large conductance Ca2+-activated K+ (BKCa) channels, which can be closely correlated with the 
significant vasorelaxant effect mediated by Nar on rat endothelium-denuded vessels16. Similar conclusions have 
been drawn by other authors: the relaxant effect of Nar on rat colon smooth muscle has been attributed to the 
direct activation of BKCa channels, resulting in hyperpolarization of smooth muscle cells, which in turn reduces 
the Ca2+ influx through voltage-dependent calcium channels17. Nar is a powerful inhibitor (IC50 of 0.5 μM) of 
the melastatin-related transient receptor potential TRPM3 belonging to the TRP family, a calcium-permeable 
non-selective cation channel expressed in various neural and non-neural tissues, activated by neurosteroids and 
heat18. Since TRPM3-deficient mice display an impaired perception of noxious heat, the inhibition of TRPM3 
may represent a novel tool for analgesic therapy19. Another member of the TRP family, TRPP2 or polycystin-2, 
a Ca2+-permeable non-selective cation channel located in the endoplasmic reticulum and in the primary cilium, 
is modulated by Nar concentrations ranging from 50 to 200 μM20. This channel is implicated in the development 
of autosomal dominant polycystic kidney disease (ADPKD). It has been suggested that Nar may activate TRPP2 
to cause Ca2+ influx and a decrease in cellular proliferation, thereby providing a novel therapeutic approach to 
ADPKD20. It is noteworthy that all the aforementioned effects are fully reversible upon Nar removal from the 
extracellular solution. Prompted by evidence pointing to Ca2+ as a possible mediator of biological responses to 
Nar, we explored the involvement of an emerging family of intracellular channels known as two-pore channels 
(TPCs). In humans, two TPC members are present, namely hTPC2, which targets lysosomes, and hTPC1, which 
is more widely distributed within the endolysosomal system despite being expressed predominantly in endo-
somes21, 22. The only member of the TPC family present in the model plant Arabidopsis thaliana is AtTPC1, which 
has been shown23 to encode the so-called, previously described, SV current24. The structure of AtTPC1 was very 
recently revealed by X-ray crystallography25–27. The structure of TPCs is dimeric with each subunit being formed 
by two covalently-linked, shaker-like domains28. From the functional point of view, hTPC2 is gated by the pow-
erful Ca2+ mobilizer Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP)21, 29, 30, although the binding of 
NAADP is likely to be mediated by a small accessory protein31–33 that has yet to be identified. Besides NAADP, 
hTPC2 is also directly activated by the phosphoinositide PI(3,5)P234–36. TPC2 knock out mice, when fed with a 
Western-type diet rich in cholesterol, suffered of non-alcoholic fatty liver hepatitis with enhanced hepatic cho-
lesterol accumulation and hyperlipoproteinaemia37; however, TPC2 deficient mice fed with a standard diet were 
identical to wild type37. Interestingly, hTPC2 has recently been related to a number of pathologies38, such as neu-
rodegenerative Parkinson disease39 and viral infection (i.e. Ebola virus)40, and has emerged as an important player 
in neoangiogenesis41, which is highly relevant to the purposes of this work. In vitro experiments in HUVECs, 
using either a selective NAADP antagonist (Ned-19) or anti-TPC2 shRNA, revealed a drastic inhibition of angio-
genic responses to VEGF following the significant reduction in intracellular Ca2+ mobilization. Moreover, in vivo 
experiments showed that Ned-19 inhibits VEGF-induced vessel formation in matrigel plugs, which also failed to 
occur in TPC2 −/− mice but was unaffected in TPC1 −/− mice41.
The present study investigates the ability of Nar to directly bind TPC2 and inhibit its activation as well as 
to specifically abolish the NAADP/TPC2-dependent mobilization of Ca2+ induced by VEGF. Interestingly, this 
inhibition is paralleled by an impairment in angiogenic responses to VEGF both in vitro and in an established in 
vivo murine model. Taken as a whole, these data identify TPC2 as a novel and important target for Nar, shedding 
new light on its mechanism of action.
Results
Naringenin reversibly impairs the functional activity of the human TPC2 channel. Flavonoids 
have the ability to permeate biological membranes by passive diffusion42, 43 and, as a consequence, to reach sub-
cellular compartments, such as lysosomes where hTPC2 is localized. This prompted us to investigate whether 
Nar, a main flavonoid present in human diet, was effective in modulating the activity of this channel. To test this 
hypothesis, we used a novel heterologous system recently developed for the expression and functional character-
ization of animal intracellular channels and transporters35, 44, 45. We transiently transformed protoplasts isolated 
from a mutant of Arabidopsis thaliana lacking the endogenous TPC with hTPC2 equipped with an EGFP fused 
to its C-terminus35. We applied the patch-clamp technique to vacuoles in which GFP fluorescence was clearly 
detectable on the tonoplast. The addition of 330 nM PI(3,5)P2 in the external (cytosolic) solution induced robust 
hTPC2-mediated currents, as shown in Fig. 1a where stationary currents recorded at +40 mV were plotted ver-
sus time. When 500 μM Nar was also added in the cytosolic solution a strong decrease in the activity of hTPC2 
currents was evident. Figure 1b shows control and recovery currents (ΔI) recorded in the presence of PI(3,5)P2 
subtracted by the correspondent background recorded without the phosphoinositide. Upon Nar application, cur-
rents were drastically reduced at both +40 and −40 mV voltages. Even if recorded in symmetrical concentration 
of sodium, due to a voltage-dependent block by cytosolic magnesium36, the currents at +40 mV were smaller than 
those recorded at −40 mV. Interestingly, Nar inhibition was fully reversible (Fig. 1b). The dose-response was well 
described by a Michaelis-Menten hyperbolic function (Fig. 1c), with apparent affinity constants of 180 ± 20 μM at 
+40 mV and of 240 ± 40 μM at −40 mV, therefore not significantly different.
The activity of human TPC1 channel is decreased by cytosolic naringenin. We wondered if Nar 
could modulate the other member of the TPC family in humans, namely hTPC1. We therefore performed a simi-
lar approach as for hTPC2 and expressed hTPC1 fused to an EGFP at its C-terminus in Arabidopsis Thaliana vac-
uoles lacking the endogenous TPC1. Suppl. Fig. 1a, left panel, shows that the background currents recorded in the 
absence of PI(3,5)P2 are very small in comparison to those elicited by the addition of the phosphoinositide (right 
panel). We chose a concentration of PI(3,5)P2 equal to 90 nM and therefore near to the saturation value since the 
apparent binding constant in this experimental condition was about 20 nM46; in comparison the affinity binding 
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Figure 1. Naringenin inhibits the activity of the human TPC2 channel. (a) Time course of current amplitude 
recorded in response to bath application of 330 nM PI(3,5)P2 (upper black bar) before and after adding 500 μM 
Nar (upper blue bar). Each point represents the steady-state current at +40 mV. (b) Currents mediated by 
hTPC2 and induced by the application of 330 nM PI(3,5)P2 in the cytosolic bath solution were recorded at +40 
and −40 mV (shown in the upper voltage profile) in the absence or presence of 500 μM cytosolic Nar. For the 
sake of clarity, background currents in the absence of the phosphoinositide were directly subtracted. (c) Dose–
response analysis of Nar inhibition. Inorm, the normalised current, was obtained by the ratio of currents recorded 
respectively in the presence and absence of cytosolic Nar. Both at +40 and −40 mV, normalised currents at 
different Nar concentrations were fitted with a Michaelis–Menten function (continuous lines). Data from 3 (Nar 
33 μM), 6 (Nar 100 μM) and 9 (Nar 500 μM) different vacuoles were shown as mean ± s.e.m. Values at positive 
and negative voltages, at a defined Nar concentration, were not significant (P > 0.2); values at different Nar 
concentrations and at a defined voltage (+40 or −40 mV), were statistically significant (at least P < 0.01).
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constant of PI(3,5)P2 for hTPC2 is about 140 nM35. The current-voltage relationship in the absence (empty sym-
bols) and in the presence (filled symbols) of PI(3,5)P2 was plotted in Suppl. Fig. 1b. In a recent paper46, we demon-
strated that the functionality of hTPC1 was strongly affected by both cytosolic and luminal Ca2+, namely an 
increase in cytosolic and luminal Ca2+ induced an increase and a decrease of the activity of the channel, respec-
tively. Here, our standard pipette and ionic bath solutions (see Materials and Methods) allowed us to record 
hTPC1-mediated currents at both negative and positive potentials and therefore to evaluate the effect of Nar at 
different voltages. In Suppl. Fig. 1b, at positive voltages, a voltage dependent inhibition of the hTPC1-induced 
currents due to the presence of cytosolic magnesium was also apparent46; a similar effect was recorded for hTPC2 
in Fig. 1b and by other authors36. Figure 2a showed that the addition to the cytosolic solution of 500 μM Nar (trace 
2) induced a significant decrease of hTPC1-elicited currents (trace 1) at both negative and positive voltages and 
had almost no effect in control conditions (compare trace 3 and 4). The inhibition of hTPC1 by Nar was quantified 
in the histogram of Fig. 2b; the effect was not voltage-dependent. Moreover, we verified that Nar decreased the 
activity of the endogenous Arabidopsis TPC1 (Suppl. Fig. 2) showing that the inhibition of TPC channels by Nar 
was a mechanism conserved during evolution.
Naringenin inhibits VEGF-dependent calcium mobilization in a dose-dependent manner. We 
have previously demonstrated that in HUVECs stimulated with VEGF intracellular Ca2+ mobilization is impaired 
when cells are pretreated with the NAADP antagonist Ned-1941. To characterize the possible inhibitory effect 
of Nar on the regulation of VEGF-dependent Ca2+ signaling, Ca2+ imaging experiments were performed on 
cells pretreated for 30 min with different concentration of Nar and then stimulated with 100 ng/ml VEGF. Ca2+ 
mobilization was significantly reduced in a dose dependent manner (Fig. 3a,b) without substantial impairment of 
VEGFR2 phosphorylation (Suppl. Fig. 3), hence downstream of receptor activation. Choosing 1000 µM Nar for its 
powerful inhibitory effect we tested the specificity of this response for NAADP/TPC2-dependent Ca2+ signaling 
using positive and negative control agonists. Nar treatment was observed to block histamine-evoked Ca2+ release 
known to be NAADP/TPC2-dependent47 (Fig. 3d), but failed to block Ca2+ response to ATP (Fig. 3c), known to 
be IP3-dependent and NAADP–independent. In addition, to more directly assess the specific inhibitory effect of 
Figure 2. The activity of the human TPC1 channel is inhibited by naringenin. (a) Currents (lower panel) 
recorded in control conditions (trace 4) or adding in the cytosolic bath solution: 90 nM PI(3,5)P2 (trace 1), 
90 nM PI(3,5)P2 and 500 μM Nar (trace 2), 500 μM Nar (trace 3). In the upper panel the voltage profile is shown. 
(b) Percentage of current inhibition induced by 500 μM Nar added in the cytosolic solution at −40 and + 40 mV. 
Data from 6 different vacuoles, shown as mean ± s.e.m., were not statistically significant (P > 0.6).
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Nar treatment on TPC2, HUVECs were stimulated with the cell permeant form of NAADP, the selective TPC2 
agonist. Ca2+ imaging experiments with 500 nM NAADP-AM were performed in a Ca2+-free buffer so as to 
monitor only internal mobilization. The histogram in Fig. 3e shows that Nar treatment significantly impairs intra-
cellular Ca2+ release at both 1000 µM and 500 µM. Nar selectivity on NAADP/TPC2 pathway was further tested 
by the use of Ang-1, an angiogenic agonist known to elicit NAADP-independent Ca2+ mobilization48. Figure 3f 
and Suppl. Fig. 4a show that Ca2+ mobilization stimulated by Ang-1 is not inhibited respectively by Nar and by 
Ned-19. Collectively, these data are a strong indication that the inhibition of hTPC2 by Nar is responsible for the 
reduced Ca2+ release.
The role of naringenin in the angiogenic process in vitro and in vivo. The formation of capillary-like 
tubes in vitro is commonly considered as representative of later, differentiative, steps of angiogenesis and is tested 
to assess the efficiency of compounds as pro- or antiangiogenic. HUVECs plated onto matrigel matrix adhere, 
migrate and, within a few hours, differentiate into capillary-like structures, a process enhanced by VEGF. An 
approximate estimate of the efficiency of this process can be evaluated by the extent of cellular network formation, 
whereby cells first align to form linear segments, which subsequently interconnect to form closed polygonal struc-
tures. As shown in Fig. 4a,b, the number of closed polygons formed in cells stimulated with VEGF in the pres-
ence of 500 µM Nar was significantly reduced (*P < 0.01) compared with samples stimulated with VEGF alone. 
The inhibitory effect of Nar on the in vitro angiogenic process was seen also with 1000 µM Nar (Suppl. Fig. 5). 
Figure 3. Naringenin inhibits Ca2+ release from HUVEC acidic stores under VEGF or NAADP-AM 
stimulation. Ca2+ imaging experiments. (a,b) Cells were pretreated for 30 min with different concentrations 
of Nar and then stimulated with 100 ng/ml VEGF; (a) Bar chart showing maximum Ca2+ concentrations; (b) 
Changes in Ca2+ levels shown as representative traces. (c,d) Cells were pretreated with 1000 µM Nar for 30 min, 
then stimulated with (c) 10 µM ATP (negative control) or (d) 100 µM histamine (positive control). (e,f) Cells 
were pretreated with 500 µM or 1000 µM Nar and then stimulated with (e) 500 nM NAADP-AM or (f) 100 ng/
ml Ang-1. Data in bar charts were from 3 independent experiments, n = 41–180 cells. *P < 0.05; **P < 0.01; 
***P < 0.001. Neither 500 µM Nar nor 1000 µM Nar significantly inhibited Ang-1 mediated Ca2+ release 
(P > 0.2).
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Interestingly, the ability of HUVECs to form closed polygons under Ang-1 stimulation was neither affected by 
treatment with 500 µM Nar (Fig. 4c,d) nor with 100 µM Ned-19 (Suppl. Fig. 4b). These findings indicate that in the 
regulation of capillary-like formation in vitro Nar specifically inhibits NAADP/TPC2-mediated Ca2+ signalling.
The specific role of Nar in the control of VEGF-induced angiogenesis is schematically represented in Fig. 5, 
based on present and previous data.
Figure 4. Naringenin impairs VEGF-induced vessel formation in vitro. (a) Representative images of one of 
three independent experiments. HUVECs were plated in Matrigel-coated dishes and incubated for 3–4 h in 
EBM-2 + 2% FBS supplemented or not with VEGF or Nar, or in medium containing both VEGF and Nar. 
(c) Representative images of one of three independent experiments. HUVECs were plated in Matrigel-coated 
dishes and incubated for 2–3 h in EGM-2 supplemented or not with Ang-1 or Nar, or in medium containing 
both Ang-1 and Nar. (b,d) Quantitative evaluation of tube formation as the number of closed polygons 
formed in 6 fields for each experimental condition for VEGF (b) and Ang-1 (d). Data in bar charts represent 
mean ± s.e.m. of three independent experiments. *P < 0.05.
Figure 5. Simplified representation of differential Ca2+ signalling pathways involved in the control of 
angiogenesis by VEGF and Ang-1. Calcium signalling is inhibited by Nar when mediated by TPC2 but not by 
RyR/InsP3R. AC: acidic compartments, ER: endoplasmic reticulum.
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The involvement of NAADP-mediated Ca2+ signaling in the regulation of the in vivo angiogenic process has 
been previously demonstrated in a murine model41. In the present study, to assess the inhibitory effect of Nar 
on in vivo angiogenesis, matrigel plug assays were performed. Five days after subcutaneous injections of plugs 
in C57BL/6 mice, the extent of plug vascularization under different experimental conditions was evaluated by 
measuring the hemoglobin (Hb) content. As macroscopically apparent (Fig. 6a), the plugs containing VEGF, but 
not those containing VEGF plus Nar or vehicle alone, underwent intense vascularization. Hb content in the plugs 
containing VEGF plus Nar was significantly lower than in the plugs containing VEGF alone (Fig. 6b). Conversely, 
in vivo vascularization induced by Ang-1 was not significantly affected by Nar (Suppl. Fig. 6).
Discussion
In this work we show that intracellular TPC channels are a target for Nar and that this flavonoid can specifically 
inhibit the ability of TPC2 to elicit Ca2+ release from acidic compartments in NAADP-mediated responses to dif-
ferent agonists i.e. VEGF and histamine. We have previously demonstrated in endothelial cells that TPC2 plays an 
essential role in the intracellular Ca2+ increase elicited by histamine and VEGF41, 47, 49, which in turn affects Von 
Willebrand factor secretion and pathophysiological neoangiogenesis respectively.
TPCs are members of the voltage-gated ion channel superfamily and localize in acidic Ca2+ stores; in par-
ticular TPC2, which has a more restricted subcellular localization, is expressed predominantly in late endosomes 
and lysosomes21. The fact that TPCs have been implicated in different pathophysiological processes38, 50 has led to 
numerous studies being conducted on their mechanism of action in an attempt to identify a drug that regulates 
TPC activity. In this study, we used electrophysiological tests to investigate the effects of the flavonoid Nar on 
intracellular TPC channels and assessed whether VEGF action, which relies upon TPC2 as a hub for intracellular 
signaling, was consequently affected. We recently developed a heterologous system for functional expression 
of animal TPC channels, namely plant vacuoles from Arabidopsis knock-out plants lacking endogenous TPC 
channels35. When we expressed hTPC2 in this TPC-free model lysosome, we found that hTPC2 share a similar 
set of inhibitors35, such as the generic ion channel blocker zinc, the Ca2+channel inhibitor verapamil and the 
antibiotic neomycin, with the plant TPC51. Accordingly, here we discovered that Nar reduced hTPC2 activity in 
a voltage-independent and reversible manner, with an IC50 of about 200 μM. We also succeeded in expressing 
the other member of the TPC family present in humans, namely hTPC1, in our plant system and verified that 
Nar behaved as a channel inhibitor in this case as well. Similarly, Nar reduced the activity of the endogenous 
Arabidopsis TPC1, thereby indicating that the mechanism is conserved from the evolutionary point of view.
Interestingly, the physical-chemical characteristics of flavonoids indicate that these compounds cross biolog-
ical membranes. Therefore, Nar might permeate the cellular membrane and reach intracellular compartments 
such as endosomes and lysosomes in which TPC channels are localised. To assess the possible effects of Nar on 
TPC2 in human cells, we first tested the ability of Nar to inhibit the Ca2+-activated responses of HUVECs to 
VEGF, which are known to depend upon the NAADP/TPC2-regulated pathway41. Our Ca2+ imaging data show 
that Nar inhibited the increase in [Ca2+]i elicited by both VEGF and histamine (positive control47) but not that 
elicited by ATP or Ang-1, which are known to be independent of NAADP/TPC2 (negative controls48).
Figure 6. Naringenin impairs in vivo vascularization induced by VEGF in C57BL/6 mice. In vivo vessel 
formation was assessed after subcutaneous injection of 5 weeks old male/female C57BL/6 mice with Matrigel 
plugs containing either vehicle or VEGF or VEGF plus 1000 μM Nar. Five days after injection the mice were 
sacrificed and plug vascularization was evaluated both macroscopically, as shown in two representative images (a) 
and as hemoglobin content expressed as absorbance (OD)/1 g matrigel plug (b); values from three independent 
experiments are expressed as mean ± s.e.m. *P < 0.05. n = 14–15 plugs for each experimental condition.
www.nature.com/scientificreports/
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As our previous data have shown41, VEGF stimulation triggers the NAADP/TPC2/Ca2+ cascade by induc-
ing phosphorylation of VEGFR2 at Tyr1175. Here we show that VEGF-induced phosphorylation of VEGFR2 
is not affected by Nar, thereby demonstrating that inhibition of the response pathway occurs downstream of 
the receptor. In another set of experiments, we further restricted the possible targets of Nar inhibition to TPC2 
by stimulating the cells directly with NAADP, which is known to bind TPC2 and elicit Ca2+ release from acidic 
compartments. Ca2+ imaging experiments with NAADP-AM were performed in the absence of external Ca2+ in 
order to monitor the involvement from internal stores alone, thus limiting possible off-target responses. In this 
experimental condition, the NAADP-induced mobilization of Ca2+ was significantly inhibited by pretreatment 
with Nar. This observation strongly suggests a direct effect of Nar on TPC2 given the specificity of the agonist and 
the preclusion of Ca2+ entry through ion channels or pumps localized on the cell membrane.
The antiangiogenic effects of Nar have recently been reported to involve impairment of the synthesis of 
estrogen-related receptor α (ERRα) and VEGF secretion4, though the specific cascade of signaling events has yet 
to be understood. Given the involvement of NAADP/TPC2 in the response to VEGF, we explored whether inhibi-
tion of this pathway by Nar might account for the reported impairment of angiogenesis. To this end, we compared 
the ability of Nar to interfere with the formation of capillary-like tubes in HUVEC cultures treated either with 
VEGF or with Ang-1. As expected, both factors stimulated the formation of short segments, which became inter-
connected within hours and formed closed polygons. Interestingly, the number of closed polygons was reduced 
by Nar in VEGF-stimulated though not in Ang-1-stimulated samples, which allowed NAADP-insensitive Ca2+ 
stores to be ruled out as Nar targets.
In addition, we successfully tested the antiangiogenic effect of Nar in a mammalian in vivo model of neoangi-
ogenesis. In a previous article by our group41 we showed that VEGF-treated plugs implanted in the flank of wild 
type mice not only failed to be vascularized if treated with the NAADP inhibitor Ned-19, but more strikingly 
remained avascular in TPC2 −/− mice; moreover, the specific need for functional TPC2 channels is clearly high-
lighted by the observation that vascularization was not inhibited in plugs from TPC1 −/− mice41. In our exper-
imental murine model of matrigel plug, neo-vascularization stimulated by VEGF was observed in the control 
samples but failed to occur in Nar-treated plugs. We cannot exclude the possibility that targets other than TPC2 
may contribute to the observed effect in vivo but these data open an interesting perspective towards a potential 
therapeutic approach.
Besides confirming the inhibitory properties of Nar in VEGF-induced angiogenesis, the data from the present 
study shed new light on the mechanisms underlying this event by revealing the pivotal role played by TPC2 and 
provide the first evidence of the antiangiogenic properties of Nar in an in vivo murine model.
Significant inhibitory effects were observed in our study at high Nar concentrations. In another study, which 
was conducted on SCID mice52 animal survival was unaffected by i.p. injections of doses of up to 5 mM Nar. The 
possible application of these data to human therapies may be hampered by problems related to the low oral bio-
availability of Nar (see ref. 53 as an example to enhance the solubility and enteral uptake of Nar) and restrictions 
imposed by clinical trials, though these issues are beyond the scope of this study.
Nar is known to exert a wide range of effects induced by a number of mechanisms that have yet to be discov-
ered. By contrast, a limited number of factors are known to modulate TPC2 activity, and our data shed light on a 
novel, naturally-occurring molecule that targets this channel which is attracting a considerable amount of interest 
owing to its relevance to important pathophysiological processes. The relationship we describe here between 
naringenin and TPC2 is therefore likely to have wider implications in systems other than the vascular system, thus 
representing a novel tool for experimental, and possibly even clinical, research purposes.
Materials and Methods
Arabidopsis protoplast transformation. Arabidopsis thaliana tpc1–2 mutants23 were grown in soil in a 
growth chamber at 22 °C and 8 h light/16 h dark regime. Well-expanded leaves from 4 weeks old plants were used 
for mesophyll protoplast preparation as described in refs 44 and 54. The transient transformation was performed 
as described previously35, 46 using the pSAT-hTPC2-EGFP or pSAT-hTPC1-EGFP plasmid as reported therein. 
The transformed cells were maintained in the dark at 23 °C in W5 ionic solution (in mM: 154 NaCl, 125 CaCl2, 
KCl 5, MES 2, pH 5.6 with KOH) plus 50 µg/ml Ampicillin as described in ref. 44. Vacuoles were efficiently 
released from the protoplasts using the following vacuole release solution (in mM): 100 malic acid, 5 EGTA, 3 
MgCl2, pH 7.5 using 160 1,3-bis(tris(hydroxymethyl)methylamino) propane (BTP), 450 mOsm with D-sorbitol.
Patch-clamp recordings. Patch-clamp experiments on vacuoles from fluorescent protoplasts expressing 
the hTPC2-EGFP fusion on the tonoplast were performed in whole-vacuole configuration ≥40 h after the trans-
formation. The bath solution (cytoplasmic side) contained (in mM): 100 NaCl, 2 MgCl2, 10 Hepes-Tris, pH 7.5. 
The pipette solution (vacuolar side) was (in mM): 100 NaCl, 2 MgCl2, 10 MES-Tris, pH 5.5. The bath solution 
and the pipette solution were adjusted to 580 mOsm and 618 mOsm by the addition of D-sorbitol. Dithiothreitol 
(DTT; 2 mM) was added to the vacuole release solution before the patch-clamp experiments. DTT was prepared 
as 1 M stock solution the day of the experiment and kept on ice until use. Nar was also prepared fresh just before 
use as 1000 mM stock in DMSO. Since the usual maximum concentration of Nar used in electrophysiological 
studies (100 μM) induced about 40% inhibition of hTPC2 and even less of AtTPC1, we decided to increase [Nar] 
up to 1000 μM. However, some precipitate was present in these conditions possibly slightly reducing the nominal 
Nar concentration. We also verified that the maximum DMSO concentration used in this study (up to 0.1%) were 
not effective on channel activity. PI(3,5)P2, purchased as dioctanyl ester (diC8) from AG Scientific or Echelon 
Biosciences Inc, was prepared as 1 mM stock solution and stored at −20 °C. The other chemicals (including Nar) 
were purchased from Sigma-Aldrich and Carl Roth.
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Analysis of electrophysiological data. Positive currents correspond to cations flowing from the cyto-
plasmic side to the lumen of the vacuole. Data analysis and figure preparation were done with Igor Pro software 
(Wavemetrics) or Photoshop (Adobe Inc.).
Cell culture. HUVECs were obtained from Lonza Sales Ldt, cultured in EGM-2 Endothelial Cell Growth 
Medium-2 (Endothelial Basal Medium EBM-2 + EGM-2 Bullet Kit, Lonza), + 100 mM Penicillin/Streptomycin 
(Sigma), maintained at 37 °C in a humidified 5% CO2 incubator and were used at passage 1 to 6. Reagents used 
are: VEGF-A165 (Peprotech), Ang-1 (Peprotech), Histamine (Sigma), ATP (Sigma), Ned-19 (Tocris Bioscience); 
NAADP-AM was a generous gift of G. C. Churchill (Oxford University).
Calcium imaging. Cells were incubated in EGM-2 containing 3.5 µM Fura-2-AM (Invitrogen) for 1 h at 37 °C 
and then rinsed with either Hanks’ Balanced Salt Solution (HBSS, Sigma) or Ca2+ free Krebs Henseleit Hepes 
buffer (KHH). Dishes were placed into a culture chamber kept at 37 °C controlled temperature on the stage of 
an inverted microfluorimeter (Nikon TE2000E) connected to a cooled CCD camera (512B Cascade, Princeton 
Instruments). Samples were illuminated alternately at 340 and 380 nm using a random access monochromator 
(Photon Technology International) and emission was detected using a 510 nm emission filter. Images were acquired 
(1 ratio image/s) using Metafluor software (Universal Imaging Corporation). Calibration of the signal was obtained 
at the end of each experiment by maximally increasing intracellular Ca2+-dependent Fura-2 fluorescence ratio 
(340/380) with 5 µM ionomycin (ionomycin calcium salt from Streptomyces conglobatus, Sigma) followed by 
recording minimal ratio in Ca2+-free medium. [Ca2+]i was calculated according to previously described formulas55.
Western Blot. HUVECs were first starved in EBM-2 + 2% FBS for 4 h and then incubated with Nar for 
30 min or with TSU-68 (SU6668, Selleckchem), an inhibitor of VEGFR2 tyrosine kinase activity, for 1 h before 
VEGF stimulation for 15 min. The primary antibody used was anti-Phospho-VEGF Receptor 2 (Tyr1175) (Cell 
Signaling Technology) revealed by Goat Anti-Rabbit IgG (H+L)-HRP Conjugate (BIO-RAD). To ensure equal 
loading, membranes were reprobed with Monoclonal Anti-α-Tubulin antibody (Sigma) followed by Goat 
Anti-Mouse IgG (H+L)-HRP Conjugate (BIO-RAD). The intensity of western blot bands was quantified by 
Image Lab 5.2.1 software (BIO-RAD) from three independent experiments.
In vitro angiogenesis assay. Capillary-like endothelial tube formation was evaluated by an in vitro angio-
genesis assay. 130 µl Matrigel Basement membrane Matrix Growth factor Reduced (BD Biosciences) was added 
to each well of pre-cooled 24-well tissue culture plates. Pipette tips and matrigel solution were kept cold during 
the procedure to avoid solidification. The plates were incubated for 1 h at 37 °C to allow matrix solution to solidify. 
4 × 104 HUVECs in a final volume of 500 µl EBM-2 + 2% FBS were seeded in each matrix-coated well. Cells were 
pretreated with 500 µM or 1000 µM Nar or with vehicle alone and stimulated with 100 ng/ml VEGF for 3–4 hours 
at 37 °C. Cells stimulated with 100 ng/ml Ang-1 for 2–3 hours, pretreated with 500 µM Nar or 100 µM Ned-19, 
were seeded in EGM-2. Tube formation was inspected under an inverted microscope (Nikon Eclipse TS100) and 
images were acquired by a digital camera (Nikon Ds Fi2, Nis elements F 4.00.00 software). The closed polygons 
formed in at least six random view microscopic fields per well were counted and values averaged.
In vivo angiogenesis assay. The ability of Nar to modulate VEGF-induced neovascularization was tested 
by matrigel plug assay. Matrigel (600 μl, BD Biosciences) supplemented with heparin (32 U/ml, Schwarz Pharma 
S.p.A), VEGF (100 ng/ml, Peprotech) or Angiopoietin1 (150 ng/ml, Peprotech), TNF-α (2 ng/ml, R&D Systems) 
and ±1000 μM Nar was injected subcutaneously into C57BL/6 mice flanks where it rapidly formed a gel. The 
negative controls contained heparin alone, the positive controls heparin plus VEGF and TNF-α. In this assay, 
cells from the surrounding tissues migrate into the matrigel plug and form vascular structures connected to the 
mouse blood vessels. After 5 days, mice were sacrificed by CO2 asphyxia and the angiogenic response was eval-
uated by macroscopic analysis at necropsy and by measurement of the hemoglobin content in the matrigel plug. 
Hemoglobin was mechanically extracted in water and measured using the Drabkin method by spectrophotomet-
rical analysis (Sigma) at 540 nm. The values were expressed as optical density/100 mg matrigel.
The animals were housed in the accredited animal facility of the Department of Anatomy, Histology, Forensic 
Medicine and Orthopaedics, Unit of Histology and Medical Embryology, Sapienza University of Rome, in individual 
cages, in an environmentally controlled room (23 °C, 12 h light-dark cycle) and provided with food and water ad libi-
tum. All of the procedures were approved by the Italian Ministry for Health and conducted according to Italian law.
Statistical analysis. Data are presented as the mean ± s.e.m. of results from at least three independent 
experiments. Student’s t test was used for statistical comparison between means where applicable. *P < 0.05; 
**P < 0.01; ***P < 0.001.
Ethical Standards. All the experiments described in this manuscript fully comply with the current laws of Italy.
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